| Year |
Citation |
Score |
| 2024 |
Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, Shaw K, van Besien K, Gomez-Arteaga A, Stevens D, Ortuzar W, Michelet X, Smith R, Moskowitz D, Masakayan R, et al. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nature Communications. 15: 974. PMID 38321023 DOI: 10.1038/s41467-024-44905-z |
0.331 |
|
| 2024 |
Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet. Oncology. PMID 38309282 DOI: 10.1016/S1470-2045(23)00649-6 |
0.361 |
|
| 2024 |
Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Shapiro RM, DeAngelo DJ, Stone RM, Bat-Erdene D, et al. Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML. Blood Advances. PMID 38197938 DOI: 10.1182/bloodadvances.2023012120 |
0.344 |
|
| 2023 |
Little JS, Duléry R, Shapiro RM, Aleissa MM, Prockop SE, Koreth J, Ritz J, Antin JH, Cutler C, Nikiforow S, Romee R, Issa NC, Ho VT, Baden LR, Soiffer RJ, et al. Opportunistic Infections in Patients Receiving Post-Transplant Cyclophosphamide: Impact of Haploidentical Versus Unrelated Donor Allograft. Transplantation and Cellular Therapy. PMID 37984797 DOI: 10.1016/j.jtct.2023.11.015 |
0.317 |
|
| 2023 |
Shapiro RM, Kim HT, Ansuinelli M, Guleria I, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Ritz J, Wu CJ, Soiffer RJ, Ho VT, Nikiforow S, Romee R. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Advances. PMID 37216223 DOI: 10.1182/bloodadvances.2023009657 |
0.371 |
|
| 2023 |
Maurer K, Ho VT, Inyang E, Cutler CS, Koreth J, Shapiro RM, Gooptu M, Romee R, Nikiforow S, Antin JH, Wu CJ, Ritz J, Soiffer RJ, Kim HT. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Advances. PMID 37156098 DOI: 10.1182/bloodadvances.2023009791 |
0.351 |
|
| 2023 |
Vergara-Cadavid J, Johnson PC, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, Gooptu M, Kelkar A, Wells SL, Nikiforow S, Koreth J, et al. Clinical Features of AKI in the Early Post-Transplant Period Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy. PMID 37015320 DOI: 10.1016/j.jtct.2023.03.029 |
0.338 |
|
| 2023 |
Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, ... Nikiforow S, et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplantation and Cellular Therapy. PMID 36906275 DOI: 10.1016/j.jtct.2023.03.006 |
0.31 |
|
| 2023 |
Maurer K, Kim HT, Garrity HM, Liney D, Cutler CS, Antin JH, Koreth J, Ritz J, Shapiro RM, Romee R, Ho VT, Gooptu M, Soiffer RJ, Wu CJ, Nikiforow S. Lower Incidence of Chronic GVHD Observed after Transplantation with Cryopreserved Unrelated Allogeneic Stem Cells. Blood Advances. PMID 36595453 DOI: 10.1182/bloodadvances.2022009231 |
0.313 |
|
| 2022 |
Kim HT, Koreth J, Whangbo J, Nikiforow S, Reynolds CG, Stowe P, Ho VT, Cutler CS, Antin JH, Soiffer RJ, Ritz J. Organ-specific response after low-dose interleukin-2 therapy for steroid refractory chronic Graft-versus-Host Disease. Blood Advances. PMID 35617682 DOI: 10.1182/bloodadvances.2022007773 |
0.308 |
|
| 2022 |
Rambaldi B, Kim HT, Arihara Y, Asano T, Reynolds C, Manter M, Halpern M, Weber A, Koreth J, Cutler C, Gooptu M, Nikiforow S, Ho VT, Antin JH, Romee R, et al. Phenotypic and functional characterization of the CD6-ALCAM T cell costimulatory pathway after allogeneic cell transplantation. Haematologica. PMID 35484649 DOI: 10.3324/haematol.2021.280444 |
0.349 |
|
| 2022 |
Whangbo J, Nikiforow S, Kim HT, Wahl J, Reynolds CG, Chamling Rai S, Kim S, Burden AT, Alho A, Lacerda JF, Alyea EP, Cutler CS, Ho VT, Antin JH, Soiffer RJ, et al. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Advances. PMID 35475885 DOI: 10.1182/bloodadvances.2021006625 |
0.442 |
|
| 2022 |
Gooptu M, Kim HT, Jacobsen ED, Fisher DC, LaCasce AS, Ho VT, Cutler CS, Koreth J, Soiffer RJ, Antin JH, Berliner N, Nikiforow S. Favorable Outcomes Following Allogeneic Transplantation in Adults with Hemophagocytic Lymphohistiocytosis. Blood Advances. PMID 35439287 DOI: 10.1182/bloodadvances.2022007012 |
0.36 |
|
| 2022 |
Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, Rambaldi B, Arihara Y, Reynolds C, Halpern MS, Rodig SJ, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. The Journal of Clinical Investigation. PMID 35349491 DOI: 10.1172/JCI154334 |
0.362 |
|
| 2021 |
Nauffal M, Kim HT, Richardson PG, Soiffer RJ, Antin JH, Cutler CS, Nikiforow S, Gooptu M, Koreth J, Romee R, Ho VT. Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. Blood Advances. PMID 34666352 DOI: 10.1182/bloodadvances.2021005410 |
0.317 |
|
| 2021 |
Maurer K, Kim HT, Kuczmarski TM, Garrity HM, Weber A, Reynolds CG, Liney D, Cutler CS, Antin JH, Koreth J, Ritz J, Shapiro RM, Romee R, Wu CJ, Soiffer RJ, ... Nikiforow S, et al. Impact of Cryopreservation and Transit Times of Allogeneic Grafts on Hematopoietic and Immune Reconstitution. Blood Advances. PMID 34581754 DOI: 10.1182/bloodadvances.2021005139 |
0.377 |
|
| 2021 |
Kim HT, Baker PO, Parry E, Davids M, Alyea EP, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Antin JH, Ritz J, Soiffer RJ, Wu CJ, et al. Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. PMID 34435483 DOI: 10.3324/haematol.2021.279033 |
0.31 |
|
| 2021 |
Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, ... ... Nikiforow S, et al. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. PMID 33720354 DOI: 10.1182/blood.2021010867 |
0.407 |
|
| 2021 |
Maurer K, Saucier A, Kim HT, Acharya U, Mo CC, Porter J, Albert C, Cutler C, Antin JH, Koreth J, Gooptu M, Romee R, Wu CJ, Soiffer RJ, Nikiforow S, et al. COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances. 5: 861-871. PMID 33560397 DOI: 10.1182/bloodadvances.2020003883 |
0.415 |
|
| 2021 |
Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Arihara Y, Kubo T, Buon L, Gooptu M, Koreth J, Cutler C, Nikiforow S, Ho VT, Alyea EP, Antin JH, Wu CJ, et al. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Advances. 5: 352-364. PMID 33496734 DOI: 10.1182/bloodadvances.2020003005 |
0.438 |
|
| 2021 |
Maurer K, Saucier A, Kim H, Acharya UH, Mo C, Porter J, Albert C, Wu CJ, Soiffer R, Cutler C, Nikiforow S, Jacobson CA, Ho VT. Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience Transplantation and Cellular Therapy. 27: S350-S351. DOI: 10.1016/S2666-6367(21)00450-4 |
0.317 |
|
| 2020 |
Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, et al. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplantation. PMID 32895491 DOI: 10.1038/S41409-020-01049-0 |
0.376 |
|
| 2020 |
Kim HT, Shaughnessy CJ, Rai SC, Reynolds C, Ho VT, Cutler C, Koreth J, Gooptu M, Romee R, Nikiforow S, Armand P, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, et al. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances. 4: 4113-4123. PMID 32882002 DOI: 10.1182/Bloodadvances.2020002184 |
0.492 |
|
| 2020 |
Rubin DB, Al Jarrah A, Li K, LaRose S, Monk AD, Ali AB, Spendley LN, Nikiforow S, Jacobson C, Vaitkevicius H. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. Jama Neurology. PMID 32777012 DOI: 10.1001/Jamaneurol.2020.2703 |
0.404 |
|
| 2020 |
Davids MS, Kim HT, Costello C, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Anderson A, Boardman AP, Weber A, Avigan D, Chen YB, Nikiforow S, Ho VT, et al. A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. PMID 32478814 DOI: 10.1182/Blood.2019004710 |
0.395 |
|
| 2020 |
Leick M, Gittelman RM, Yusko E, Sanders C, Robins H, DeFilipp Z, Nikiforow S, Ritz J, Chen YB. T-cell clonal dynamics determined by high resolution TCR-β sequencing in recipients after allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32417490 DOI: 10.1016/J.Bbmt.2020.04.026 |
0.511 |
|
| 2020 |
Espada E, Cheng MP, Kim HT, Woolley AE, Avigan JI, Forcade E, Soares MVD, Lacerda JF, Nikiforow S, Gooptu M, Romee R, Alyea EP, Armand P, Cutler CS, Ho VT, et al. BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances. 4: 1881-1893. PMID 32374880 DOI: 10.1182/Bloodadvances.2019001120 |
0.446 |
|
| 2020 |
Hickey CL, Romee R, Nikiforow S, Dorfman D, Mazzeo M, Koreth J. A case of Epstein-Barr virus-related lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide. Haematologica. PMID 32241847 DOI: 10.3324/Haematol.2019.236067 |
0.447 |
|
| 2020 |
Miller PG, Niroula A, Ceremsak JJ, Gibson CJ, Taylor MS, Birndt S, Perner F, Arnason J, Sperling AS, Agrawal M, Schram AM, Nikiforow S, Pihan G, Hasserjian RP, Aster JC, et al. Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances. 4: 925-929. PMID 32150605 DOI: 10.1182/Bloodadvances.2019001272 |
0.339 |
|
| 2020 |
Shah O, Tamaresis JS, Kenyon LJ, Xu L, Zheng P, Gupta P, RangarajanK K, Lee S, Spellman S, Nikiforow S, Zehnder J, Meyer EH. Analysis of Whole CDR3 TCR Repertoire after Hematopoietic Stem Cell Transplantation in Two Clinical Cohorts. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32081787 DOI: 10.1016/J.Bbmt.2020.01.020 |
0.504 |
|
| 2020 |
Rambaldi B, Kim HT, Reynolds C, Chamling Rai S, Asano T, Arihara Y, Gooptu M, Koreth J, Cutler C, Nikiforow S, Ho VT, Antin JH, Romee R, Soiffer RJ, Ampudia J, et al. Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab Blood. 136: 10-11. DOI: 10.1182/blood-2020-138710 |
0.356 |
|
| 2020 |
Baker KP, Shapiro RM, Reynolds C, Rambaldi B, Weber A, Dal Boni M, Koreth J, Cutler C, Antin JH, Ho VT, Nikiforow S, Gooptu M, Wu CJ, Soiffer RJ, Ritz J, et al. Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution Blood. 136: 12-13. DOI: 10.1182/BLOOD-2020-136390 |
0.403 |
|
| 2020 |
Shapiro RM, Nikiforow S, Rambaldi B, Vergara J, Daley H, Kim HT, Cutler C, Ho VT, Koreth J, Gooptu M, Antin JH, Brock J, Wu CJ, Soiffer RJ, Ritz J, et al. Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial Blood. 136: 8-9. DOI: 10.1182/BLOOD-2020-133933 |
0.375 |
|
| 2020 |
Hamilton E, Nikiforow S, Bardwell P, McInnis C, Zhang J, Blumenschein G, Cristea M, Osman K, Shields A, Motta M, Bilic S, Schoenborn-Kellenberger O, Rakestraw J, Carey S, Geretti E, et al. 801 PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients Journal For Immunotherapy of Cancer. 8: A850-A850. DOI: 10.1136/jitc-2020-sitc2020.0801 |
0.36 |
|
| 2020 |
Ganatra S, Redd R, Hayek S, Parikh R, Azam T, Yanik G, Spendley L, Nikiforow S, Jacobson C, Nohria A. Cardiovascular effects of chimeric antigen receptor t-cell therapy for refractory or relapsed non-hodgkin lymphoma European Heart Journal. 41. DOI: 10.1093/ehjci/ehaa946.3263 |
0.347 |
|
| 2020 |
Nikiforow S, King B, Garrity H, Rosati C, Wood A, Nolan M, Smith S, Powers M, Albert C, Stasko K, Schott D, Kelley M, Sturtevant OJ, Jacobsen E, Ritz J, et al. Donor risk factors and recipient clinical impact of positive microbial contamination after bone marrow harvests - a large academic medical center experience Cytotherapy. 22. DOI: 10.1016/J.Jcyt.2020.03.324 |
0.368 |
|
| 2020 |
Prockop SE, Reshef R, Tsai DE, Bunin N, Abu-Arja R, Mahadeo KM, Weng W, van Besien K, Loeb D, Nasta SD, Nemecek ER, Hiremath M, Yue S, Sun Y, Navarro WH, ... Nikiforow S, et al. Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study Biology of Blood and Marrow Transplantation. 26: S61-S62. DOI: 10.1016/J.Bbmt.2019.12.228 |
0.415 |
|
| 2020 |
Rambaldi B, Kim HT, Reynolds C, Rai SC, Gooptu M, Koreth J, Cutler C, Nikiforow S, Ho VT, Alyea EP, Antin JH, Wu CJ, Soiffer RJ, Ritz J, Romee R. NK Cell Impairment after Haploidentical Allogeneic Hematopoietic Cell Transplant in Patients Receiving Post-Transplant Cyclophosphamide (PTCy) Biology of Blood and Marrow Transplantation. 26: S70-S71. DOI: 10.1016/J.Bbmt.2019.12.218 |
0.515 |
|
| 2019 |
Lewis C, Kim HT, Roeker LE, Cutler C, Koreth J, Nikiforow S, Armand P, Gootpu M, Romee R, Glotzbecker B, Nageshwar P, Antin JH, Alyea EP, Richardson P, Soiffer RJ, et al. Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced intensity allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31678537 DOI: 10.1016/J.Bbmt.2019.10.024 |
0.409 |
|
| 2019 |
DeFilipp Z, Li S, Avigan D, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Ritz J, Boussiotis V, Rosenblatt J, Brown J, McAfee S, Dey BR, El-Jawahri A, et al. A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplantation. PMID 31616065 DOI: 10.1038/S41409-019-0715-X |
0.396 |
|
| 2019 |
Nikiforow S, Berliner N. To "lump" or to "split" in Macrophage Activation Syndrome and Hemophagocytic Lymphohistiocytosis. Arthritis & Rheumatology (Hoboken, N.J.). PMID 31524337 DOI: 10.1002/Art.41106 |
0.339 |
|
| 2019 |
Whangbo JS, Kim HT, Mirkovic N, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds CG, Rai SC, Verrill K, Lee MA, Margossian S, Duncan C, Lehmann L, Huang J, ... Nikiforow S, et al. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Advances. 3: 2550-2561. PMID 31471324 DOI: 10.1182/Bloodadvances.2019000631 |
0.385 |
|
| 2019 |
Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, ... ... Nikiforow S, et al. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Advances. 3: 2199-2204. PMID 31324640 DOI: 10.1182/Bloodadvances.2019000445 |
0.422 |
|
| 2019 |
Whangbo JS, Kim HT, Nikiforow S, Koreth J, Alho AC, Falahee B, Kim S, Dusenbury K, Fields MJ, Reynolds CG, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, et al. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Advances. 3: 984-994. PMID 30936059 DOI: 10.1182/Bloodadvances.2018027474 |
0.456 |
|
| 2019 |
Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, Hipolito E, Savage WJ, Reynolds CG, Fields MJ, Whangbo J, Kubo T, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, et al. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Advances. 3: 969-979. PMID 30936057 DOI: 10.1182/Bloodadvances.2018029124 |
0.482 |
|
| 2019 |
Esrick EB, Achebe M, Armant M, Bartolucci P, Ciuculescu MF, Daley H, Dansereau C, Di Caprio G, Goncalves B, Hebert N, Heeney MM, Higgins JM, Lehmann LE, Manis JP, Negre O, ... Nikiforow S, et al. Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing Blood. 134: LBA-5-LBA-5. DOI: 10.1182/Blood-2019-132745 |
0.397 |
|
| 2019 |
Jaglowski S, Hu Z, Zhang Y, Kamdar M, Ghosh M, Lulla P, Sasine J, Perales M, Hematti P, Nikiforow S, Steinert P, Jeschke M, Yi L, Chawla R, Pacaud L, et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry Blood. 134: 766-766. DOI: 10.1182/Blood-2019-130983 |
0.364 |
|
| 2019 |
Grupp S, Hu Z, Zhang Y, Keating A, Pulsipher MA, Philips C, Margossian SP, Rosenthal J, Salzberg D, Schiff DE, Yanik G, Curran KJ, Harris AC, Hematti P, Nikiforow S, et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry Blood. 134: 2619-2619. DOI: 10.1182/Blood-2019-129279 |
0.341 |
|
| 2019 |
Garcia JS, Kim HT, Brock J, Han A, Ryan JA, Mashaka T, Letai AG, Lindsley RC, Gooptu M, Ho VT, Koreth J, Nikiforow S, Romee R, Galinsky I, Wadleigh M, et al. A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patients with High Risk Myeloid Malignancies Blood. 134: 258-258. DOI: 10.1182/Blood-2019-126172 |
0.413 |
|
| 2019 |
Rambaldi B, Reynolds C, Rai SC, Asano T, Arihara Y, Gooptu M, Koreth J, Cutler C, Nikiforow S, Ho VT, Alyea EP, Antin JH, Romee R, Soiffer RJ, Russo D, et al. Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease Blood. 134: 4517-4517. DOI: 10.1182/Blood-2019-125721 |
0.397 |
|
| 2019 |
Prockop S, Reshef R, Tsai DE, Bunin N, Abu-Arja R, Mahadeo KM, Weng W, Van Besien K, Loeb D, Dwivedy Nasta S, Nemecek ER, Hiremath M, Yue S, Sun Y, Navarro W, ... Nikiforow S, et al. Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program Blood. 134: 4071-4071. DOI: 10.1182/Blood-2019-124904 |
0.43 |
|
| 2019 |
Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Ghobadi A, Komanduri KV, Hu Z, Dong H, Hematti P, Nikiforow S, Steinert P, Purdum A, Horowitz MM, Hooper M, Kawashima J, et al. Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US) Blood. 134: 764-764. DOI: 10.1182/Blood-2019-124750 |
0.32 |
|
| 2019 |
Hickey CL, Kim HT, Ho VT, Nikiforow S, Gooptu M, Koreth J, Ritz J, Romee R, Alyea EP, Soiffer RJ, Antin JH, Cutler C. Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leukemia Undergoing Myeloablative Allogeneic Transplantation Blood. 134: 263-263. DOI: 10.1182/Blood-2019-122257 |
0.366 |
|
| 2019 |
Hickey CL, Kim HT, Nikiforow S, Gooptu M, Koreth J, Ritz J, Ho VT, Alyea EP, Soiffer RJ, Antin JH, Cutler C, Romee R. Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation Blood. 134: 4486-4486. DOI: 10.1182/Blood-2019-121659 |
0.411 |
|
| 2019 |
Pasquini M, Hu Z, Zhang Y, Grupp S, Hematti P, Jaglowski S, Keating A, Nikiforow S, Philips C, Pulsipher M, Shah S, Steinert P, Yanik G, Wang H, Horowitz M, et al. Real World Experience of Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cells Targeting CD19 in Patients with Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry Clinical Lymphoma Myeloma and Leukemia. 19: S267. DOI: 10.1016/J.Clml.2019.07.190 |
0.471 |
|
| 2019 |
Nikiforow S, Berliner N, Kim HT, Ho VT, Joyce A, Glotzbecker B, Alyea EP, Armand P, Cutler C, Gooptu M, Koreth J, Ritz J, Romee R, Soiffer RJ, Antin JH. Genetic Predispositions, Management Strategies, and Clinical Outcomes in Adults with Hemophagocytic Lymphohistiocytosis (HLH) after Reduced-Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation (HSCT) at Dana-Farber Cancer Institute Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.812 |
0.483 |
|
| 2019 |
Rambaldi B, Kim HT, Reynolds C, Fields M, Rai SC, Gooptu M, Koreth J, Cutler C, Nikiforow S, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Romee R. Dynamics of Immune Cell Reconstitution in Allogeneic Hematopoietic Cell Transplant Patients Receiving Post-Transplant Cyclophosphamide (PTCy) Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.528 |
0.506 |
|
| 2019 |
Solle JC, Close S, Spendley L, Laubach J, Richardson PG, King B, Amenta J, Haiman S, Metellus J, Klinker K, Garrity H, Stasko K, Schott D, Sturtevant O, Ritz J, ... ... Nikiforow S, et al. Making Room in the Parking Lot for More Cars - How Changes to Autologous Collection Targets for Patients with Multiple Myeloma Optimized Resource Utilization in the Apheresis Collection Center and Cell Storage Facility at Dana-Farber Cancer Institute Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.320 |
0.395 |
|
| 2019 |
Whangbo J, Kim HT, Stewart J, Leonard L, Poryanda S, Silverstein S, Kim S, Reynolds C, Fields M, Verrill K, Lee M, Margossian S, Duncan C, Lehmann LE, Nikiforow S, et al. Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates Biology of Blood and Marrow Transplantation. 25: S16-S17. DOI: 10.1016/J.Bbmt.2018.12.084 |
0.37 |
|
| 2018 |
Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, ... ... Nikiforow S, et al. Phase 1 Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunology Research. PMID 30396908 DOI: 10.1158/2326-6066.Cir-18-0307 |
0.464 |
|
| 2018 |
Esrick EB, Manis JP, Daley H, Baricordi C, Trébéden-Negre H, Pierciey FJ, Armant M, Nikiforow S, Heeney MM, London WB, Biasco L, Asmal M, Williams DA, Biffi A. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Advances. 2: 2505-2512. PMID 30282642 DOI: 10.1182/Bloodadvances.2018016725 |
0.452 |
|
| 2018 |
Nikiforow S. Finding "intermediate" ground in transplant and HLH. Blood. 132: 1361-1363. PMID 30262583 DOI: 10.1182/Blood-2018-08-870014 |
0.396 |
|
| 2018 |
Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, ... ... Nikiforow S, et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 20: 952-963. PMID 30180944 DOI: 10.1016/J.Jcyt.2018.05.001 |
0.417 |
|
| 2018 |
Roeker LE, Kim HT, Glotzbecker B, Nageshwar P, Nikiforow S, Koreth J, Armand P, Cutler C, Alyea EP, Antin JH, Richardson PG, Soiffer RJ, Ho VT. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 30081073 DOI: 10.1016/J.Bbmt.2018.07.039 |
0.396 |
|
| 2018 |
Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, et al. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. PMID 30076185 DOI: 10.3324/Haematol.2017.182550 |
0.392 |
|
| 2018 |
Torre M, Solomon IH, Sutherland CL, Nikiforow S, DeAngelo DJ, Stone RM, Vaitkevicius H, Galinsky IA, Padera RF, Trede N, Santagata S. Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. Journal of Neuropathology and Experimental Neurology. PMID 30060228 DOI: 10.1093/Jnen/Nly064 |
0.423 |
|
| 2018 |
Gooptu M, Kim HT, Ho VT, Alyea EP, Koreth J, Armand P, Ritz J, Nikiforow S, Glotzbecker BE, Nageshwar P, Soiffer RJ, Antin JH, Cutler CS. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem-Cell Transplantation in the Modern Era: a Cohort Analysis. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29555313 DOI: 10.1016/J.Bbmt.2018.03.011 |
0.441 |
|
| 2018 |
Koreth J, Kim HT, Lange PB, Poryanda SJ, Reynolds CG, Chamling Rai S, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf R, Nikiforow S, Chen YB, Dey B, McMasters M, et al. Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. PMID 29326124 DOI: 10.3324/Haematol.2017.176859 |
0.41 |
|
| 2018 |
Davids MS, Kim HT, Costello CL, Herrera AF, Locke FL, Maegawa RO, Savell A, Mazzeo M, Avigan DE, Chen Y, Nikiforow S, Ho VT, Cutler CS, Alyea EP, Bachireddy P, et al. A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT) Blood. 132: 705-705. DOI: 10.1182/Blood-2018-99-117671 |
0.329 |
|
| 2018 |
Esrick EB, Brendel C, Manis JP, Armant MA, Negre H, Dansereau C, Ciuculescu MF, Patriarca S, Mackinnon B, Daley H, Richard S, Abriss D, Maxwell R, Braunewell S, Christiansen L, ... Nikiforow S, et al. Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients Blood. 132: 1023-1023. DOI: 10.1182/Blood-2018-99-116733 |
0.465 |
|
| 2018 |
Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP, et al. Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant Blood. 132: 817-817. DOI: 10.1182/Blood-2018-99-113911 |
0.432 |
|
| 2018 |
Lewis C, Kim HT, Cutler CS, Koreth J, Nikiforow S, Gooptu M, Romee R, Glotzbecker B, Nageshwar P, Alyea EP, Antin JH, Richardson P, Soiffer RJ, Ho VT. Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Blood. 132: 3376-3376. DOI: 10.1182/Blood-2018-99-113130 |
0.391 |
|
| 2018 |
Kubo T, Romee R, Koreth J, Belizaire R, Kamihara Y, Liu H, Asano T, Whangbo J, Hirakawa M, Nikiforow S, Gooptu M, Ho VT, Cutler CS, Alyea EP, Antin JH, et al. Low-Dose Interleukin-2 Therapy Enhances Cytotoxicity of CD56bright NK Cells in Patients with Chronic Gvhd Blood. 132: 606-606. DOI: 10.1182/Blood-2018-99-109918 |
0.409 |
|
| 2018 |
Daley H, Richard S, Negre H, Nikiforow S, Sturtevant OJ, Wood A, Kelley M, Ritz J. Developing a robust competency program for the GMP novel cell therapy laboratory in the cell manipulation core facility laboratory at Dana-Farber Cancer Institute, Boston Cytotherapy. 20. DOI: 10.1016/J.Jcyt.2018.02.224 |
0.313 |
|
| 2018 |
Stasko K, Close S, King B, Geary J, Garrity H, Schott D, Bagley J, Crown D, Ellis M, Sturtevant OJ, Emmert AE, Ritz J, Nikiforow S. How optimizing efficiency for autologous stem cell collection can set the stage for novel cell therapy growth in multiple departments Cytotherapy. 20. DOI: 10.1016/J.Jcyt.2018.02.207 |
0.335 |
|
| 2018 |
Kekre N, Kim HT, Ho VT, Guo Y, Mahmood U, Belatreche W, Koreth J, Armand P, Nikiforow S, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri AR, Soiffer RJ, Antin JH, et al. Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids as Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.649 |
0.301 |
|
| 2018 |
Kamihara Y, Forcade E, Koreth J, Kim HT, Liu H, Douchet I, Kubo T, Whangbo J, Hirakawa M, Nikiforow S, Ho VT, Armand P, Cutler C, Alyea EP, Blanco P, et al. Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells (cTFR) and Suppresses Circulating T Follicular Helper Cells (cTFH) in Patients with Chronic Gvhd Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.617 |
0.441 |
|
| 2018 |
Whangbo JS, Kim HT, Nikiforow S, Koreth J, Kim S, Alyea EP, Armand P, Cutler C, Ho VT, Antin JH, Soiffer RJ, Ritz J. Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.616 |
0.431 |
|
| 2018 |
Prockop SE, Li A, Baiocchi R, Bunin NJ, Mahadeo KM, Nemecek ER, Nikiforow S, Reshef R, Tsai DE, Navarro WH, O'Reilly RJ. Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder Biology of Blood and Marrow Transplantation. 24: S41-S42. DOI: 10.1016/J.Bbmt.2017.12.595 |
0.391 |
|
| 2017 |
Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Cin PD, Pak C, Alyea EP, Budde E, Chen R, Chen YB, ... ... Nikiforow S, et al. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29196080 DOI: 10.1016/J.Bbmt.2017.11.023 |
0.427 |
|
| 2017 |
Wang KS, Kim HT, Nikiforow S, Heubeck AT, Ho VT, Koreth J, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Cutler CS, Ritz J. Antibodies Targeting Surface Membrane Antigens in Patients with Chronic Graft-Versus-Host Disease. Blood. PMID 29138220 DOI: 10.1182/Blood-2017-08-801001 |
0.391 |
|
| 2017 |
Gibson CJ, Kennedy JA, Nikiforow S, Kuo FC, Alyea EP, Ho V, Ritz J, Soiffer R, Antin JH, Lindsley RC. Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. PMID 28446434 DOI: 10.1182/Blood-2017-01-764951 |
0.426 |
|
| 2017 |
Maus MV, Nikiforow S. The Why, what, and How of the New FACT standards for immune effector cells. Journal For Immunotherapy of Cancer. 5: 36. PMID 28428885 DOI: 10.1186/S40425-017-0239-0 |
0.439 |
|
| 2017 |
Kekre N, Kim HT, Ho VT, Cutler C, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J. Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. PMID 28341735 DOI: 10.3324/Haematol.2017.164012 |
0.432 |
|
| 2017 |
Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, ... ... Nikiforow S, et al. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016716712. PMID 28068180 DOI: 10.1200/Jco.2016.71.6712 |
0.445 |
|
| 2017 |
Nikiforow S, Kim HT, Jones KT, Stewart J, Garrity H, Daley H, Richard S, Manduke R, Chammas M, Reynolds C, Burden A, Whangbo J, Blazar B, Armand P, Ho VT, et al. Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease Blood. 130: 511-511. DOI: 10.1182/Blood.V130.Suppl_1.511.511 |
0.434 |
|
| 2017 |
Prockop S, Li A, Baiocchi RA, Bunin N, Mahadeo KM, Nemecek ER, Nikiforow S, Reshef R, Tsai DE, Navarro WH, O'Reilly RJ. Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder Blood. 130: 4520-4520. DOI: 10.1182/Blood.V130.Suppl_1.4520.4520 |
0.375 |
|
| 2017 |
Forcade E, Kamihara Y, Kim HT, Douchet I, Koreth J, Hirakawa M, Cutler C, Nikiforow S, Ho VT, Armand P, Alyea E, Blanco P, Blazar B, Antin JH, Soiffer RJ, et al. T Follicular Regulatory (TFR) Cell Deficiency during Chronic Graft-Versus-Host Disease Is Improved By Low-Dose IL-2 Therapy Blood. 130: 4439-4439. DOI: 10.1182/Blood.V130.Suppl_1.4439.4439 |
0.415 |
|
| 2017 |
Cutler CS, Li S, Avigan DE, Armand P, Ho VT, Koreth J, Nikiforow S, Boussiotis VA, Rosenblatt J, Dowling M, McAfee SL, Dey BR, El-Jawahri AR, Spitzer TR, Chen Y, et al. No Change in Viral Infections, But Low Relapse Rate, with the Elimination of Anti-Thymocyte Globulin Prior to Double Umbilical Cord Blood Transplantation Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.284 |
0.354 |
|
| 2016 |
Nikiforow S, Li S, Snow K, Liney D, Kao GS, Haspel R, Shpall EJ, Glotzbecker B, Sica RA, Armand P, Koreth J, Ho VT, Alyea EP, Ritz J, Soiffer RJ, et al. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. PMID 27939176 DOI: 10.1016/J.Jcyt.2016.10.016 |
0.364 |
|
| 2016 |
Hirakawa M, Matos T, Liu H, Koreth J, Kim HT, Paul NE, Murase K, Whangbo J, Alho AC, Nikiforow S, Cutler C, Ho VT, Armand P, Alyea EP, Antin JH, et al. Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells. Jci Insight. 1: e89278. PMID 27812545 DOI: 10.1172/Jci.Insight.89278 |
0.416 |
|
| 2016 |
Herrera AF, Kim HT, Kong KA, Faham M, Sun H, Sohani AR, Alyea EP, Carlton VE, Chen YB, Cutler CS, Ho VT, Koreth J, Kotwaliwale C, Nikiforow S, Ritz J, et al. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. British Journal of Haematology. PMID 27711974 DOI: 10.1111/Bjh.14311 |
0.432 |
|
| 2016 |
Brunner AM, Li S, Fathi AT, Wadleigh M, Ho VT, Collier K, Connolly C, Ballen KK, Cutler CS, Dey BR, El-Jawahri A, Nikiforow S, McAfee SL, Koreth J, Deangelo DJ, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. British Journal of Haematology. PMID 27434660 DOI: 10.1111/Bjh.14260 |
0.376 |
|
| 2016 |
Nikiforow S, Kim HT, Daley H, Reynolds C, Jones KT, Armand P, Ho VT, Alyea EP, Cutler CS, Ritz J, Antin JH, Soiffer RJ, Koreth J. A phase I study of CD25/regulatory T cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. PMID 27354021 DOI: 10.3324/Haematol.2015.141176 |
0.48 |
|
| 2016 |
Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft vs. host disease. Blood. PMID 27073224 DOI: 10.1182/Blood-2016-02-702852 |
0.423 |
|
| 2016 |
Forcade E, Kim HT, Cutler C, Wang K, Alho AC, Nikiforow S, Ho VT, Koreth J, Armand P, Alyea EP, Blazar BR, Soiffer RJ, Antin JH, Ritz J. Circulating T follicular helper cells with increased function during chronic graft-versus-host-disease. Blood. PMID 26944544 DOI: 10.1182/Blood-2015-12-688895 |
0.489 |
|
| 2016 |
Martin PS, Li S, Nikiforow S, Alyea EP, Antin JH, Armand P, Cutler CS, Ho VT, Kekre N, Koreth J, Luckey CJ, Ritz J, Soiffer RJ. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. PMID 26768686 DOI: 10.3324/Haematol.2015.134841 |
0.48 |
|
| 2016 |
Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop H, Rooney CM, et al. Erratum: CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo (Science Translational Medicine (2016) 8:321 (321er1)) Science Translational Medicine. 8. PMID 26764153 DOI: 10.1126/Scitranslmed.Aaf1718 |
0.394 |
|
| 2016 |
Nikiforow S, Ritz J. Dramatic Expansion of HSCs: New Possibilities for HSC Transplants? Cell Stem Cell. 18: 10-2. PMID 26748750 DOI: 10.1016/J.Stem.2015.12.011 |
0.378 |
|
| 2016 |
Nikiforow S, Murad J, Daley H, Negre H, Reder J, Sentman CL, Lehmann F, Snykers S, Allen R, Galinsky I, Munshi NC, Stone RM, Soiffer R, Ritz J, Baumeister SH. A first-in-human phase I trial of NKG2D chimeric antigen receptor-T cells in AML/MDS and multiple myeloma. Journal of Clinical Oncology. 34: TPS3102-TPS3102. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps3102 |
0.424 |
|
| 2016 |
Gibson CJ, Kennedy JA, Nikiforow S, Dick JE, Ritz J, Soiffer RJ, Antin JH, Lindsley RC. Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation Blood. 128: 987-987. DOI: 10.1182/Blood.V128.22.987.987 |
0.453 |
|
| 2016 |
Gibson CJ, Lindsley RC, Tchekmedyian V, Shi J, Mar BG, Jaiswal S, Bosworth A, Francisco LF, He J, Morgan EA, LaCasce AS, Koreth J, Ho VT, Ritz J, Nikiforow S, et al. Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma Blood. 128: 986-986. DOI: 10.1182/Blood.V128.22.986.986 |
0.397 |
|
| 2016 |
Herrera AF, Song JY, Griffin GK, Nikolaenko L, Mei M, Bedell V, Cin PD, Pak C, Stiller T, Sun H, Alyea EP, Budde LE, Chen RW, Chen Y, Chan WC, ... ... Nikiforow S, et al. Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation Blood. 128: 830-830. DOI: 10.1182/Blood.V128.22.830.830 |
0.346 |
|
| 2016 |
Wang KS, Cutler CS, Nikiforow S, Ho VT, Koreth J, Alyea EP, Armand P, Soiffer RJ, Antin JH, Ritz J. Enhanced B-Cell Differentiation and Increased Production of Antibodies Targeting Surface Membrane Antigens in Patients with Chronic Graft-Versus-Host Disease Blood. 128: 670-670. DOI: 10.1182/Blood.V128.22.670.670 |
0.474 |
|
| 2016 |
Whangbo J, Falahee B, Koreth J, Kim HT, Nikiforow S, Ho VT, Cutler CS, Armand P, Alyea EP, Antin JH, Soiffer RJ, Ritz J. Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease Blood. 128: 667-667. DOI: 10.1182/Blood.V128.22.667.667 |
0.432 |
|
| 2016 |
Koreth J, Kim HT, Lange PB, Armand P, Cutler CS, Ho VT, Glotzbecker B, Yusuf RZ, Nikiforow S, Dey BR, McMasters M, Ritz J, Blazar BR, Soiffer RJ, Antin JH, et al. Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial Blood. 128: 508-508. DOI: 10.1182/Blood.V128.22.508.508 |
0.414 |
|
| 2016 |
Nikiforow S, Werner L, Murad J, Jacobs M, Johnston L, Patches S, White R, Daley H, Negre H, Reder J, Sentman C, Wade T, Schmucker A, Lehmann FF, Snykers S, et al. Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma Blood. 128: 4052-4052. DOI: 10.1182/Blood.V128.22.4052.4052 |
0.502 |
|
| 2016 |
Espada E, Woolley AE, Avigan J, Forcade E, Soares MVD, Nikiforow S, Ho VT, Cutler CS, Koreth J, Armand P, Alyea EP, Soiffer RJ, Antin JH, Lacerda JF, Kim HT, et al. BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation Blood. 128: 3425-3425. DOI: 10.1182/Blood.V128.22.3425.3425 |
0.501 |
|
| 2016 |
Nikiforow S, Winawer-Wetzel S, Phicil S, Lowery K, Glotzbecker B, Clements M, Mersereau R, Sturtevant O, Galinsky I, Savage WJ, Alyea EP, Soiffer RJ, Bunnell C, Emmert A. A Systematic Approach to Providing Safe Quality Care for Patients Receiving Engineered, Non-Stem Cell Therapies Blood. 128: 2371-2371. DOI: 10.1182/Blood.V128.22.2371.2371 |
0.367 |
|
| 2016 |
Daley H, Nikiforow S, Murad J, Negre H, Reider J, Sentman C, Snykers S, Allen R, Galinsky I, Munshi N, Stone R, Soiffer R, Ritz J, Baumeister S. 71. Validation of Manufacturing NKG2D Chimeric Antigen Receptor T Cells for a First-In-Human Clinical Trial in AML/MDS and Multiple Myeloma Molecular Therapy. 24: S31. DOI: 10.1016/S1525-0016(16)32880-5 |
0.474 |
|
| 2016 |
Kekre N, Kim HT, Ho VT, Koreth J, Armand P, Glotzbecker B, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Marty F, Cutler CS. Cytomegalovirus Reactivation Does Not Reduce the Risk of Disease Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 22. DOI: 10.1016/J.Bbmt.2015.11.807 |
0.421 |
|
| 2016 |
Salit RB, Emerson R, Karanes C, Gutman JA, Nikiforow S, Duncan C, Kurtzberg J, Robins H, Rieder M, Delaney C. Interim Analysis of an Observational Study Assessing T Cell Receptor Diversity As an Early Predictor of NRM in Cord Blood Transplant Recipients Biology of Blood and Marrow Transplantation. 22: S44. DOI: 10.1016/J.Bbmt.2015.11.326 |
0.434 |
|
| 2015 |
El-Jawahri A, Li S, Antin JH, Spitzer TR, Armand PA, Koreth J, Nikiforow S, Ballen KK, Ho VT, Alyea EP, Dey BR, McAfee SL, Glotzbecker BE, Soiffer RJ, Cutler CS, et al. Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in The Modern Years. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26748160 DOI: 10.1016/J.Bbmt.2015.12.024 |
0.429 |
|
| 2015 |
Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, Whangbo J, Nikiforow S, Cutler CS, Koreth J, Ho VT, Armand P, Antin JH, Alyea EP, Lacerda JF, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. PMID 26670634 DOI: 10.1182/Blood-2015-10-672345 |
0.488 |
|
| 2015 |
Nikiforow S. The Role of Hematopoietic Stem Cell Transplantation in Treatment of Hemophagocytic Lymphohistiocytosis. Hematology/Oncology Clinics of North America. 29: 943-59. PMID 26461153 DOI: 10.1016/J.Hoc.2015.06.011 |
0.408 |
|
| 2015 |
Politikos I, Kim HT, Nikiforow S, Li L, Brown J, Antin JH, Cutler C, Ballen K, Ritz J, Boussiotis VA. IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. Plos One. 10: e0132564. PMID 26177551 DOI: 10.1371/Journal.Pone.0132564 |
0.389 |
|
| 2015 |
Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler C, Nikiforow S, Ho VT, Koreth J, Alyea EP, Soiffer RJ. Efficacy of immune suppression taper in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. PMID 26088931 DOI: 10.3324/Haematol.2015.129650 |
0.455 |
|
| 2015 |
Koreth J, Kim HT, Lange PB, Bindra B, Reynolds CG, Chammas MJ, Armand P, Cutler CS, Ho VT, Glotzbecker B, Nikiforow S, Ritz J, Blazar BR, Soiffer RJ, Antin JH, et al. A Bortezomib-based Regimen Offers Promising Survival and Graft-vs.-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 26055298 DOI: 10.1016/J.Bbmt.2015.05.027 |
0.471 |
|
| 2015 |
Nikiforow S, Ritz J. Reconstitution of T Cell Immunity after Umbilical Cord Blood Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1151-2. PMID 25985916 DOI: 10.1016/J.Bbmt.2015.04.027 |
0.436 |
|
| 2015 |
Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, et al. CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Science Translational Medicine. 7: 285ra63. PMID 25925682 DOI: 10.1126/Scitranslmed.Aaa2546 |
0.467 |
|
| 2015 |
Hirakawa M, Matos TR, Koreth J, Forcade E, Whangbo J, Murase K, Liu H, Nikiforow S, Ho VT, Cutler CS, Armand P, Alyea EP, Antin JH, Soiffer RJ, Ritz J. IL-2 Induces Selective Activation of Helios-Positive Regulatory T Cells and CD56bright NK Cells in Vitro and in Patients with Chronic Gvhd Receiving Low-Dose IL-2 Therapy Blood. 126: 919-919. DOI: 10.1182/Blood.V126.23.919.919 |
0.423 |
|
| 2015 |
Nikiforow S, Hemmer M, Spellman SR, Alousi AM, Couriel DR, Pidala JA, Arora M, Cutler CS, Wang T. Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations Blood. 126: 857-857. DOI: 10.1182/Blood.V126.23.857.857 |
0.416 |
|
| 2015 |
Kekre N, Kim HT, Ho VT, Cutler CS, Armand P, Nikiforow S, Alyea EP, Soiffer RJ, Antin JH, Connors JM, Koreth J. Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Blood. 126: 742-742. DOI: 10.1182/Blood.V126.23.742.742 |
0.401 |
|
| 2015 |
Whangbo J, Koreth J, Kim HT, Dusenbury K, Alho AC, Reynolds CG, Chammas MJ, Jones KT, Nikiforow S, Cutler CS, Ho VT, Armand P, Alyea EP, Soiffer RJ, Antin JH, et al. Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease Blood. 126: 3133-3133. DOI: 10.1182/Blood.V126.23.3133.3133 |
0.396 |
|
| 2015 |
Forcade E, Paula S, Cowens K, Bento ML, Nikiforow S, Koreth J, Cutler CS, Ho VT, Armand P, Alyea EP, Soiffer RJ, Antin JH, Blazar BR, Ritz J. Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.240 |
0.45 |
|
| 2015 |
Hanley PJ, Melenhorst J, Nikiforow S, Scheinberg P, Cruz R, Krance RA, Leung K, Martinez C, Heslop HE, Rooney CM, Barrett AJ, Shpall EJ, Bollard CM. CMVpp65-Specific T Cells Generated from Naïve T Cell Populations Recognize Atypical but Not Canonical Epitopes and May Be Protective In Vivo Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.049 |
0.386 |
|
| 2014 |
Nikiforow S, Alyea EP. Maximizing GVL in allogeneic transplantation: role of donor lymphocyte infusions. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2014: 570-5. PMID 25696913 DOI: 10.1182/Asheducation-2014.1.570 |
0.482 |
|
| 2014 |
Singh H, Nikiforow S, Li S, Ballen KK, Spitzer TR, Soiffer R, Antin JH, Cutler C, Chen YB. Outcomes and management strategies for graft failure after umbilical cord blood transplantation. American Journal of Hematology. 89: 1097-101. PMID 25195500 DOI: 10.1002/Ajh.23845 |
0.455 |
|
| 2014 |
Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP, Armand P, Cutler CS, Ho VT, Nikiforow S, Blazar BR, Ritz J, Antin JH, Soiffer RJ, Koreth J. A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1737-43. PMID 25017765 DOI: 10.1016/J.Bbmt.2014.06.040 |
0.383 |
|
| 2014 |
Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, Ritz J, Alyea EP. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 1516-21. PMID 24907627 DOI: 10.1016/J.Bbmt.2014.05.025 |
0.481 |
|
| 2014 |
Nikiforow S, Lacasce AS. Targeting Epstein-Barr virus-associated lymphomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 830-2. PMID 24493729 DOI: 10.1200/Jco.2013.53.2994 |
0.463 |
|
| 2014 |
Li L, Kim HT, Nellore A, Patsoukis N, Petkova V, McDonough S, Politikos I, Nikiforow S, Soiffer R, Antin JH, Ballen K, Cutler C, Ritz J, Boussiotis VA. Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/β-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer Journal. 4: e178. PMID 24442207 DOI: 10.1038/Bcj.2013.75 |
0.438 |
|
| 2014 |
Koreth J, Kim HT, Jones KT, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP, Armand P, Cutler CS, Ho VT, Chen Y, Avigan D, Antin JH, et al. Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Phase 2 and Long Term Efficacy, Safety and Immune Correlates Blood. 124: 41-41. DOI: 10.1182/Blood.V124.21.41.41 |
0.369 |
|
| 2014 |
Herrera AF, Kim HT, Faham M, Sun H, Sohani AR, Alyea EP, Chen Y, Cutler CS, Ho VT, Koreth J, Nikiforow S, Ritz J, Rodig SJ, Soiffer RJ, Antin JH, et al. Sequencing-Based Detection of Minimal Residual Disease Is Associated with Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Lymphoid Malignancies Blood. 124: 3961-3961. DOI: 10.1182/Blood.V124.21.3961.3961 |
0.427 |
|
| 2014 |
Kekre N, Kim HT, Thanarajasingam G, Armand P, Antin JH, Cutler CS, Nikiforow S, Ho VT, Alyea EP, Koreth J, Soiffer RJ. Immunosuppression Taper to Induce Graft-Verus-Tumor Activity As the Sole Therapy for Early Relapse after Reduced Intensity Allogeneic Hematopoietic Cell Transplantation Blood. 124: 2504-2504. DOI: 10.1182/Blood.V124.21.2504.2504 |
0.449 |
|
| 2014 |
Alho AC, Haesook KT, Reynolds CG, Chammas MJ, McDonough S, Lazo-Kallanian S, Daley J, Nikiforow S, Cutler CS, Koreth J, Ho VT, Armand P, Soiffer RJ, Antin JH, Ritz J. Homeostatic Reconstitution of CD4+ Regulatory and Conventional T Cell Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Blood. 124: 2496-2496. DOI: 10.1182/Blood.V124.21.2496.2496 |
0.492 |
|
| 2014 |
Politikos I, Kim HT, Nikiforow S, Li L, Ballen KK, Antin JH, Ritz J, Cutler CS, Boussiotis VA. Prognostic Value of TREC, IL-7 and SCF Levels on Clinical Outcomes after Double Umbilical Cord Blood Transplantation in Adults Blood. 124: 2488-2488. DOI: 10.1182/Blood.V124.21.2488.2488 |
0.437 |
|
| 2014 |
Emerson RO, Nikiforow S, Milano F, Sherwood AM, Papermaster A, Guthrie KA, Carlson CS, Warren EH, Ritz J, Robins H, Cutler CS, Delaney C. TCR Repertoire Diversity Assessed with Immunosequencing Is Associated with Patient Mortality Following Cord Blood Transplant Blood. 124: 1262-1262. DOI: 10.1182/Blood.V124.21.1262.1262 |
0.481 |
|
| 2014 |
Nikiforow S, Kim HT, McDonough SM, Emerson R, Hamm D, Ballen KK, Boussiotis VA, Soiffer RJ, Antin JH, Ritz J, Cutler CS. Recipient T-Cell Repertoire Diversity after Double Umbilical Cord Transplantation Correlates with Non-Relapse Mortality and Survival Biology of Blood and Marrow Transplantation. 20: S243-S244. DOI: 10.1016/J.Bbmt.2013.12.409 |
0.44 |
|
| 2014 |
Nikiforow S, Korman S, Eapen M, Antin JH. Outcomes after Allogeneic Stem Cell Transplantation in Adults for Histiocytic Disorders Including Hemophagocytic Lymphohistiocytosis Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.408 |
0.392 |
|
| 2014 |
Politikos I, Kim HT, Nikiforow S, Nellore A, Li L, McDonough SM, Soiffer RJ, Antin JH, Ballen KK, Cutler CS, Ritz J, Boussiotis VA. Maintenance of Naïve T Cells and a Diverse TCR Repertoire Are Critical for Reconstitution of EBV-Specific Immunity after Double Cord Blood Transplantation Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.225 |
0.454 |
|
| 2014 |
Hanley PJ, Nikiforow S, Melenhorst J, Scheinberg P, Savoldo B, Dotti G, Rooney CM, Heslop HE, Shpall EJ, Barrett AJ, Bollard CM. Extending the Option of CMV-Specific T Cells from the CMV-Seronegative Donor Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.200 |
0.459 |
|
| 2014 |
Glotzbecker B, Kim HT, Cutler CS, Koreth J, Armand P, Nikiforow S, Antin JH, Soiffer RJ, Alyea EP, Ho VT. Risk Factors for Graft Failure and Survival after Reduced Intensity (RIC) Conditioning Allogeneic Hematopoietic Cell Transplantation (HCT) for Myelofibrosis Biology of Blood and Marrow Transplantation. 20. DOI: 10.1016/J.Bbmt.2013.12.021 |
0.406 |
|
| 2013 |
Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS. Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 19: 804-11. PMID 23416855 DOI: 10.1016/J.Bbmt.2013.02.009 |
0.393 |
|
| 2013 |
Nikiforow S, Li S, Coughlin E, Breault E, Liney D, Kao G, Snow K, Haspel RL, Kurtzberg J, Scaradavou A, Shpall EJ, Glotzbecker B, Armand P, Koreth J, Ho VT, et al. Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients Blood. 122: 695-695. DOI: 10.1182/Blood.V122.21.695.695 |
0.401 |
|
| 2013 |
Kim H, Nikiforow S, Nellore A, Li L, McDonough S, Soiffer RJ, Antin JH, Ballen KK, Cutler CS, Ritz J, Boussiotis VA. Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire Blood. 122: 3302-3302. DOI: 10.1182/Blood.V122.21.3302.3302 |
0.527 |
|
| 2013 |
Nikiforow S, McDonough SM, Emerson RO, Hamm D, Kim H, Ballen K, Boussiotis VA, Soiffer RJ, Antin JH, Ritz J, Cutler C. Evolution of T Cell Repertoire Diversity After Reduced-Intensity Conditioning and Double Umbilical Cord Blood Transplantation with or without Exposure to FT1050 (16,16-dimethyl Prostaglandin E2) Biology of Blood and Marrow Transplantation. 19: S206-S207. DOI: 10.1016/J.Bbmt.2012.11.230 |
0.403 |
|
| 2013 |
Nikiforow S, Kim H, Kao G, Sainvil M, McDonough SM, Armand P, Ho VT, Alyea EP, Cutler C, Ritz J, Antin JH, Soiffer RJ, Koreth J. CD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion for Relapse After Allogeneic Transplantation – A PHASE 1 Study Biology of Blood and Marrow Transplantation. 19. DOI: 10.1016/J.Bbmt.2012.11.074 |
0.48 |
|
| 2012 |
Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP, Ritz J, Soiffer RJ, Antin JH, Cutler C. A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease Blood. 120: 744-744. DOI: 10.1182/Blood.V120.21.744.744 |
0.342 |
|
| 2012 |
Li L, Nellore A, McDonough S, Politikos I, Kim H, Nikiforow S, Antin JH, Ballen KK, Cutler C, Ritz J, Boussiotis VA. Prostaglandin E2 (PGE2) Alters the Molecular and Functional Properties of Umbilical Cord Blood T Cells Via Modulating Wnt/β-Catenin Signaling Blood. 120: 226-226. DOI: 10.1182/Blood.V120.21.226.226 |
0.479 |
|
| 2011 |
Jeong JY, Silver M, Parnes A, Nikiforow S, Berliner N, Vanasse GJ. Resveratrol ameliorates TNFα-mediated suppression of erythropoiesis in human CD34(+) cells via modulation of NF-κB signalling. British Journal of Haematology. 155: 93-101. PMID 21762122 DOI: 10.1111/J.1365-2141.2011.08800.X |
0.314 |
|
| 2008 |
Parnes A, Nikiforow S, Berliner N, Vanasse KGJ. Single Nucleotide Polymorphisms in the Human TNFα Gene Are Associated with Neutropenia and Anemia in a Cohort of Patients with Myelodysplastic Syndrome Blood. 112: 3646-3646. DOI: 10.1182/Blood.V112.11.3646.3646 |
0.337 |
|
| 2008 |
Tijaro-Ovalle NM, Li S, Defilipp Z, Politikos I, Joyce RM, Armand P, Ho VT, Koreth J, Nikiforow S, Alyea EP, Avigan DE, Rosenblatt J, Brown J, McAfee S, Dey B, et al. Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4 + T Cells Blood. 112: 1167-1167. DOI: 10.1182/Blood-2019-129154 |
0.51 |
|
| 2003 |
Bickham K, Goodman K, Paludan C, Nikiforow S, Tsang ML, Steinman RM, Münz C. Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro. The Journal of Experimental Medicine. 198: 1653-63. PMID 14657218 DOI: 10.1084/Jem.20030646 |
0.42 |
|
| 2003 |
Nikiforow S, Bottomly K, Miller G, Münz C. Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. Journal of Virology. 77: 12088-104. PMID 14581546 DOI: 10.1128/Jvi.77.22.12088-12104.2003 |
0.661 |
|
| 2002 |
Paludan C, Bickham K, Nikiforow S, Tsang ML, Goodman K, Hanekom WA, Fonteneau JF, Stevanović S, Münz C. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. Journal of Immunology (Baltimore, Md. : 1950). 169: 1593-603. PMID 12133989 DOI: 10.4049/Jimmunol.169.3.1593 |
0.419 |
|
| 2001 |
Nikiforow S, Bottomly K, Miller G. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation. Journal of Virology. 75: 3740-52. PMID 11264363 DOI: 10.1128/Jvi.75.8.3740-3752.2001 |
0.652 |
|
| Show low-probability matches. |